Eli Lilly (LLY) said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Jaypirca to treat certain adult patients with relapsed or refractory chronic lymphocytic leukemia.
The recommendation is based on data from a phase 3 trial, in which the therapy met its primary endpoint of progression-free survival, Lilly said.
The European Commission will make a final decision in next one or two months, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.